LOS ANGELES, Aug. 26, 2005 (PRIMEZONE) -- BiomedDiscoveries.com, http://www.BiomedDiscoveries.com, the online source for exclusive investor information in the biotechnology sector, announced today the availability of a candid online interview with Michael Weiner, CEO of Biophan Technologies (OTCBB:BIPH), a leading developer of next-generation medical technology.
In the interview, Mr. Weiner articulates to investors and others a range of insights and observations about the medical device industry generally, and why it was so important for this Company to launch its new development division at this moment of expansion. The key to continued success for Biophan, says Mr. Weiner, is to be extremely well-prepared in every possible sense, including scientifically, technically, politically and legally, to deal effectively with "the big boys" in the industry.
The Biophan Business Development Group has been formed following Biophan's recent landmark licensing agreement with one of the world's leading medical device manufacturers, Boston Scientific.
The group's formation is designed to capitalize on Biophan's extensive IP portfolio of 144 pending and issued patents, and to further expand Biophan licensing agreements to the biomedical industry. "After five years of development, we now have demonstrated that our technology works, and we have established very broad and aggressive patents, so the next objective is to sell these technologies," Mr. Weiner notes.
In addition, the interview includes Mr. Weiner's observations about the "politics" of business growth, such as the critical need for a savvy, scientifically sophisticated and smart licensing and sales team, which he is confident that he has assembled under the stewardship of group Vice President, John Lanzafame. For example, he notes, this division would need to effectively "defend our patents and bring them to court if there is any type of patent infringement," he says.
Mr. Weiner also cites clear indications of the progress that Biophan has made in establishing itself as a recognized biotechnology leader. Nowadays, "licensing partners are calling us," he notes, whereas before, "We had to knock on doors to get attention."
Biophan's mission is to develop technologies to improve medical devices and to bring those technologies to market through strategic partnerships. Among Biophan's device-enhancing technologies are novel solutions to detect the presence of restenosis in stents or thrombosis in vena cava filters and improve the functional imaging of other vascular implants. Biophan has further developed a wide range of MRI-enabling technologies for pacemakers, defibrillators, neurostimulators, catheters, guidewires, drug pumps, and other devices. Currently, due to various safety problems, millions of patients with implanted pacemakers and neurostimulators are denied access to MRI systems. In addition, many other conventional medical devices cannot effectively be imaged under MRI.
The interview is available online at http://www.BiomedDiscoveries.com.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops technologies that enable implanted medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and devices such as stents to be safely and effectively imaged under MRI. Biophan is developing these same technologies to provide new MRI contrast agents. Other applications include drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 144 U.S. patents, licenses, or applications. This total includes 41 issued U.S. patents, 9 recently-allowed applications that will issue as patents in the near future, and 94 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development and licensing agreements with Boston Scientific (NYSE:BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.
About BiomedDiscoveries.com
BiomedDiscoveries.com provides exclusive commentary, research, interviews and other information about the smallcap investment marketplace. BiomedDiscoveries.com strives to provide investors with information and research-based data regarding important individual companies and overall marketplace trends. Resources available on BiomedDiscoveries.com include audio interviews with corporate leaders and respected commentators, as well as technical white papers and other forms of market and investment analysis. It is located at http://www.BiomedDiscoveries.com.
Forward-Looking Statements
Statements made on BiomedDiscoveries.com may contain forward-looking statements made by senior management of the companies presented here that involve risks and uncertainties, such as statements about plans, objectives, expectations, assumptions or future events. These statements involve estimates, assumptions, known and unknown risks, uncertainties and performances, or achievements expressed or implied by the forward-looking statements. Actual future results and trends may differ materially from those made in -- or suggested by -- statements presented here due to a variety of factors. Consequently, you should not place undue reliance on any forward-looking statements made here. Many of these and other risks and uncertainties are discussed in greater detail in recent filings with the Securities Exchange Commission for the companies that are present by BiomedDiscoveries.com. Compensation and Other Disclosures BiomedDiscoveries.com is a wholly-owned subsidiary of Trilogy Capital Partners, Inc. Trilogy Capital Partners provides investor relations services to public companies. The companies presented by BiomedDiscoveries.com are usually clients of Trilogy Capital Partners and compensate Trilogy Capital Partners for these services, including cash compensation and equity securities. In addition, Trilogy Capital Partners and its affiliates may own securities of the presenting companies, and may from time to time purchase and sell securities of these companies in the open market or in private transactions. Biophan Technologies pays Trilogy $12,500 per month for so long as Trilogy is retained to provide investor relations services. A subsidiary of Trilogy has entered into an agreement with a non-affiliate shareholder of this company to purchase from the shareholder 880,000 shares at $.80 per share and 4,180,000 shares at $2.00 per share at such time as the shareholder has purchased the shares from by this company at the same prices. The shareholder is obligated to purchase these shares only if this company has registered the shareholder's resale of the shares under the Securities Act of 1933 and certain other conditions are satisfied.